Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lilly and Alkermes begin late stage trial for inhaled diabetes drug
The goal of the study is to more fully define the safety and efficacy of the Lilly/Alkermes inhaled insulin system in patients with diabetes. The phase III programme
The goal of the study is to more fully define the safety and efficacy of the Lilly/Alkermes inhaled insulin system in patients with diabetes. The phase III programme
This clinical trial, the first of four phase II studies planned for OGX-011 in 2005, is designed to assess the safety and efficacy of the drug in prostate
In the main study, involving 716 patients with wet age-related macular degeneration (AMD), Lucentis was shown not only to stop the progress of the disease, but to actually
Under the terms of the transaction, Sosei will pay the $187.4 million with an upfront payment of $20.7 million in cash, and issue 35,630 shares for the rest.
Orphan drug status is granted by the FDA in order to encourage the development of treatments for rare diseases and disorders. It means that Chemokine Therapeutics will be
The drug is already indicated for the treatment of influenza in children aged one year and above, but not yet for use as a preventative in this age
Development will resume pending discussion of plans and protocols with the FDA, with a mid phase clinical trial expected to begin in the fourth quarter of 2005. The
As a subcontractor under Harvard Medical School’s award, Avant Immunotherapeutics will receive approximately $374,000 of this funding over a twelve-month period. The project will use Avant’s VitriLife technology
Currently, after angioplasty is performed to unblock narrowed coronary arteries, a patient receives anticoagulant therapies such as heparin, aspirin, and plavix. However, in 30-40% of cases the narrowing
Provecta is a small molecule, tumor-specific agent designed to treat melanoma, breast cancer, liver cancer and other potentially deadly cancers while sparing healthy tissue. Provectus expects to begin